It will take $15 billion in grants during 2022 and another $10 billion annually after that to establish and maintain an adequate toolkit to respond to COVID-19 and address future pandemic threats, according to four organizations focused on global health and the economy.

Paxlovid

Pfizer Inc. is expected to provide around 10 million courses of the company’s highly effective COVID-19 antiviral treatment Paxlovid to low-income and middle-income countries during 2022, according to an official with the Global Fund, a healthcare NGO working to buy the pills from the drugmaker.

At least $18 billion is needed to get the fight against malaria, tuberculosis and AIDS back on track from disruptions caused by the COVID-19 pandemic, a global health fund said on February 23.